loading
전일 마감가:
$6.08
열려 있는:
$6.08
하루 거래량:
101.38K
Relative Volume:
0.10
시가총액:
$478.38M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-2.0428
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
-4.91%
1개월 성능:
+20.16%
6개월 성능:
-7.19%
1년 성능:
+57.36%
1일 변동 폭
Value
$6.06
$6.33
1주일 범위
Value
$5.71
$7.33
52주 변동 폭
Value
$2.41
$7.37

솔리드 바이오 Stock (SLDB) Company Profile

Name
명칭
Solid Biosciences Inc
Name
전화
617-337-4680
Name
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Name
직원
100
Name
트위터
@SolidBioDMD
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
SLDB's Discussions on Twitter

Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SLDB
Solid Biosciences Inc
6.1401 473.69M 14.79M -102.44M -91.73M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.02 117.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
797.94 82.85B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
846.97 51.58B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.83 40.75B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
350.38 38.33B 4.98B 69.60M 525.67M 0.5198

솔리드 바이오 Stock (SLDB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-12-04 개시 Needham Buy
2025-06-26 개시 Citigroup Buy
2025-01-08 개시 Truist Buy
2024-12-13 개시 Wedbush Outperform
2024-12-10 개시 JMP Securities Mkt Outperform
2024-07-15 업그레이드 JP Morgan Neutral → Overweight
2024-06-24 업그레이드 Leerink Partners Market Perform → Outperform
2024-05-31 재개 Piper Sandler Overweight
2024-03-28 개시 William Blair Outperform
2024-03-15 개시 Citigroup Buy
2024-03-14 업그레이드 Piper Sandler Neutral → Overweight
2023-12-08 개시 H.C. Wainwright Buy
2021-07-12 개시 Piper Sandler Neutral
2021-05-27 개시 Jefferies Buy
2021-03-16 업그레이드 SVB Leerink Mkt Perform → Outperform
2021-03-09 개시 Barclays Overweight
2021-01-08 업그레이드 Credit Suisse Underperform → Neutral
2020-07-28 다운그레이드 SVB Leerink Outperform → Mkt Perform
2020-05-07 다운그레이드 Evercore ISI Outperform → In-line
2019-10-11 개시 Evercore ISI Outperform
2019-08-29 다운그레이드 Citigroup Neutral → Sell
2019-08-19 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-08-16 업그레이드 Chardan Capital Markets Neutral → Buy
2019-05-14 다운그레이드 Credit Suisse Neutral → Underperform
2019-05-14 다운그레이드 Goldman Neutral → Sell
2019-02-08 업그레이드 Citigroup Sell → Neutral
2019-02-08 다운그레이드 SVB Leerink Outperform → Mkt Perform
2018-11-06 개시 Citigroup Sell
2018-09-06 개시 Credit Suisse Neutral
모두보기

솔리드 바이오 주식(SLDB)의 최신 뉴스

pulisher
Feb 12, 2026

Solid Biosciences (SLDB) Gets a Buy from Wedbush - The Globe and Mail

Feb 12, 2026
pulisher
Feb 10, 2026

Citizens reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Nigeria

Feb 10, 2026
pulisher
Feb 10, 2026

Citizens reiterates Market Outperform rating on Solid Biosciences stock - Investing.com

Feb 10, 2026
pulisher
Feb 10, 2026

Solid Biosciences advances Duchenne treatment with FDA alignment By Investing.com - Investing.com South Africa

Feb 10, 2026
pulisher
Feb 09, 2026

Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha

Feb 09, 2026
pulisher
Feb 09, 2026

Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus

Feb 09, 2026
pulisher
Feb 09, 2026

Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences (SLDB) Gains FDA Alignment for Duchenne Trial - GuruFocus

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences Receives Positive FDA Feedback - Intellectia AI

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences stock rises after FDA alignment on Phase 3 trial design - Investing.com Australia

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences (SLDB) Advances Duchenne Therapy with FDA Support - GuruFocus

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences Aligns With FDA on Phase 3 Trial Design for Duchenne Muscular Dystrophy Gene Therapy - marketscreener.com

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Bio, FDA agree on trial for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences advances Duchenne treatment with FDA alignment - Investing.com

Feb 09, 2026
pulisher
Feb 09, 2026

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - The Manila Times

Feb 09, 2026
pulisher
Feb 09, 2026

Merger Talk: Why is Solid Biosciences Inc. stock going upWeekly Stock Analysis & Safe Entry Point Identification - baoquankhu1.vn

Feb 09, 2026
pulisher
Feb 07, 2026

Death Cross: What are Solid Biosciences Incs earnings expectations2025 Trade Ideas & Fast Entry Momentum Alerts - baoquankhu1.vn

Feb 07, 2026
pulisher
Feb 06, 2026

Solid Biosciences CTO Herzich sells $70k in SLDB stock By Investing.com - Investing.com Canada

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences chief regulatory officer sells $79,544 in SLDB By Investing.com - Investing.com UK

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences CMO Brooks sells $81k in shares By Investing.com - Investing.com South Africa

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences chief regulatory officer sells $79,544 in SLDB - Investing.com India

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences CTO Herzich sells $70k in SLDB stock - Investing.com

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences CEO Cumbo sells $315,092 in stock By Investing.com - Investing.com Canada

Feb 06, 2026
pulisher
Feb 06, 2026

Ilan Ganot, Solid Biosciences director, sells $46k in shares By Investing.com - Investing.com UK

Feb 06, 2026
pulisher
Feb 06, 2026

Ilan Ganot, Solid Biosciences director, sells $46k in shares - Investing.com

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences CEO Cumbo sells $315,092 in stock - Investing.com

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 14,783 Shares - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells 48,913 Shares of Stock - MarketBeat

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences Flies Ahead of Summit - Baystreet.ca

Feb 06, 2026
pulisher
Feb 06, 2026

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times

Feb 06, 2026
pulisher
Feb 06, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Feb 06, 2026
pulisher
Feb 03, 2026

Solid Biosciences Inc. (NASDAQ:SLDB) Sees Large Decline in Short Interest - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

Solid Biosciences COO Howton sells $243k in shares By Investing.com - Investing.com UK

Feb 03, 2026
pulisher
Feb 02, 2026

Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 26,837 Shares - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Alexander Cumbo Sells 80,258 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Gabriel Brooks Sells 28,335 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Solid Biosciences (NASDAQ:SLDB) COO Sells $243,245.24 in Stock - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Paul Herzich Sells 26,250 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

Solid Biosciences CFO sells $172k in shares By Investing.com - Investing.com UK

Feb 02, 2026
pulisher
Feb 02, 2026

Solid Biosciences CFO sells $172k in shares - Investing.com

Feb 02, 2026
pulisher
Feb 02, 2026

Solid Biosciences COO Howton sells $243k in shares - Investing.com

Feb 02, 2026
pulisher
Feb 01, 2026

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 01, 2026
pulisher
Jan 24, 2026

EPS Watch: Can Vail Resorts Inc sustain earnings growth2025 Technical Patterns & High Win Rate Trade Alerts - baoquankhu1.vn

Jan 24, 2026

솔리드 바이오 (SLDB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

솔리드 바이오 주식 (SLDB) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Cumbo Alexander
President and CEO
Feb 04 '26
Sale
6.44
48,913
315,093
222,018
Ganot Ilan
Director
Feb 04 '26
Sale
6.44
7,205
46,414
25,271
Tan Kevin
CFO & Treasurer
Feb 04 '26
Sale
6.44
14,783
95,231
94,201
Brooks Gabriel
Chief Medical Officer
Feb 04 '26
Sale
6.44
12,616
81,271
84,092
Hanrahan Jessie
Chief Regulatory Officer
Feb 04 '26
Sale
6.44
12,348
79,545
70,327
Herzich Paul
Chief Technology Officer
Feb 04 '26
Sale
6.44
10,905
70,249
69,067
$98.11
price up icon 0.78%
$45.17
price up icon 0.78%
$101.87
price up icon 0.94%
$107.39
price up icon 1.62%
$149.09
price up icon 1.99%
biotechnology ONC
$349.00
price up icon 0.60%
자본화:     |  볼륨(24시간):